Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
Ono Pharmaceutical secured 1.3% growth in its FY2019 revenue as an overall sales decline including its PD-1 inhibitor Opdivo (nivolumab) was countered by royalty income associated with Merck’s rival product Keytruda (pembrolizumab), according to its earnings released on May 12.…
To read the full story
Related Article
- Ono’s Q1 Operating Profit Up 35% as SGA, R&D Costs Decrease on COVID-19
August 3, 2020
- Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
June 8, 2020
- Ono to Test Pancreatitis Med Foipan for COVID-19: President
May 13, 2020
- Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
February 3, 2020
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…